Cited 0 time in
Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Gil-Ran | - |
| dc.contributor.author | Choi, Je-Min | - |
| dc.date.accessioned | 2023-05-03T14:19:51Z | - |
| dc.date.available | 2023-05-03T14:19:51Z | - |
| dc.date.issued | 2022-08 | - |
| dc.identifier.issn | 1016-8478 | - |
| dc.identifier.issn | 0219-1032 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/185394 | - |
| dc.description.abstract | Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an immune checkpoint molecule that is mainly expressed on activated T cells and regulatory T (Treg) cells that inhibits T-cell activation and regulates immune homeostasis. Due to the crucial functions of CTLA-4 in T-cell biology, CTLA-4-targeted immunotherapies have been developed for autoimmune disease as well as cancers. CTLA-4 is known to compete with CD28 to interact with B7, but some studies have revealed that its downstream signaling is independent of its ligand interaction. As a signaling domain of CTLA-4, the tyrosine motif plays a role in inhibiting T-cell activation. Recently, the lysine motif has been shown to be required for the function of Treg cells, emphasizing the importance of CTLA-4 signaling. In this review, we summarize the current understanding of CTLA-4 biology and molecular signaling events and discuss strategies to target CTLA-4 signaling for immune modulation and disease therapy. | - |
| dc.format.extent | 9 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 한국분자세포생물학회 | - |
| dc.title | Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.14348/molcells.2022.2056 | - |
| dc.identifier.scopusid | 2-s2.0-85136200318 | - |
| dc.identifier.wosid | 000888494800001 | - |
| dc.identifier.bibliographicCitation | Molecules and Cells, v.45, no.8, pp 513 - 521 | - |
| dc.citation.title | Molecules and Cells | - |
| dc.citation.volume | 45 | - |
| dc.citation.number | 8 | - |
| dc.citation.startPage | 513 | - |
| dc.citation.endPage | 521 | - |
| dc.type.docType | Short Survey | - |
| dc.identifier.kciid | ART002872553 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Cell Biology | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Cell Biology | - |
| dc.subject.keywordPlus | CLATHRIN-ASSOCIATED PROTEIN | - |
| dc.subject.keywordPlus | REGULATORY T | - |
| dc.subject.keywordPlus | POSTTRANSLATIONAL MODIFICATIONS | - |
| dc.subject.keywordPlus | COSTIMULATION BLOCKADE | - |
| dc.subject.keywordPlus | AUTOIMMUNE-DISEASE | - |
| dc.subject.keywordPlus | CYTOPLASMIC DOMAIN | - |
| dc.subject.keywordPlus | FOLLICULAR HELPER | - |
| dc.subject.keywordPlus | ACTIVATION | - |
| dc.subject.keywordPlus | CD28 | - |
| dc.subject.keywordPlus | ABATACEPT | - |
| dc.subject.keywordAuthor | cytotoxic T lymphocyte antigen-4 (CTLA-4) | - |
| dc.subject.keywordAuthor | immunotherapy | - |
| dc.subject.keywordAuthor | signaling motif | - |
| dc.subject.keywordAuthor | T cell | - |
| dc.subject.keywordAuthor | Treg cell | - |
| dc.subject.keywordAuthor | - | - |
| dc.identifier.url | https://www.molcells.org/journal/view.html?doi=10.14348/molcells.2022.2056 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
